Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedAug 27, 2026
DataAggregated Company Financials
Companies20
  • 7D1.1%
  • 3M5.3%
  • 1Y-11.6%
  • YTD-6.8%

Over the last 7 days, the Healthcare industry has risen 3.4%, driven by gains from Novo Nordisk of 3.9%. During this same period, the ALK-Abelló underperformed, falling 6.2%. In the past year, the industry is down 9.3%. As for the next few years, earnings are expected to grow by 4.5% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 27 Aug 2026DKK 1.8tDKK 468.2bDKK 137.3b23.2x13.2x3.9x
Sat, 25 Jul 2026DKK 1.9tDKK 469.5bDKK 147.2b20.4x12.6x3.9x
Mon, 22 Jun 2026DKK 1.7tDKK 469.0bDKK 147.1b19.6x11.6x3.6x
Wed, 20 May 2026DKK 1.7tDKK 468.7bDKK 147.0b20.2x11.5x3.6x
Fri, 17 Apr 2026DKK 1.6tDKK 447.1bDKK 129.9b19x12x3.5x
Sun, 15 Mar 2026DKK 1.5tDKK 448.1bDKK 130.1b16.8x11.6x3.4x
Tue, 10 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b16.3x13.6x4.1x
Thu, 08 Jan 2026DKK 2.1tDKK 453.9bDKK 136.9b17.6x15.6x4.7x
Sat, 06 Dec 2025DKK 1.9tDKK 454.0bDKK 137.0b17.3x13.8x4.1x
Mon, 03 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.2x13.4x4.3x
Wed, 01 Oct 2025DKK 2.0tDKK 447.3bDKK 141.7b17.6x14.2x4.5x
Fri, 29 Aug 2025DKK 2.1tDKK 447.4bDKK 141.7b24.5x14.6x4.6x
Sun, 27 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Tue, 24 Jun 2025DKK 2.5tDKK 423.4bDKK 124.6b30.4x19.7x5.8x
Thu, 22 May 2025DKK 2.5tDKK 424.3bDKK 125.1b24.1x19.9x5.9x
Sat, 19 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Mon, 17 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.9x23.5x7x
Wed, 12 Feb 2025DKK 3.2tDKK 408.3bDKK 118.3b28.1x27.1x7.8x
Fri, 10 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b30.3x30.1x8.6x
Sun, 08 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Tue, 05 Nov 2024DKK 3.9tDKK 372.2bDKK 107.2b33.2x36.5x10.5x
Thu, 03 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.4x11.1x
Sat, 31 Aug 2024DKK 4.8tDKK 371.8bDKK 107.1b35.5x44.7x12.9x
Mon, 29 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.9x42.1x12.6x
Wed, 26 Jun 2024DKK 5.1tDKK 355.3bDKK 106.2b34.3x48.3x14.5x
Fri, 24 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.6x44.6x13.3x
Sun, 21 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b33.3x44.5x13x
Tue, 19 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.2x46.9x13.7x
Thu, 15 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b34.9x44x12.7x
Sat, 13 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42x11.8x
Mon, 11 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.8x38.9x10.9x
Wed, 08 Nov 2023DKK 3.6tDKK 318.7bDKK 90.3b29.3x40.2x11.4x
Fri, 06 Oct 2023DKK 3.3tDKK 305.5bDKK 82.2b32.7x40.7x11x
Sun, 03 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Price to Earnings Ratio

42x


Total Market Cap: DKK 3.5tTotal Earnings: DKK 82.2bTotal Revenue: DKK 305.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 27.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.4x which is lower than its 3-year average PE of 27.9x.
  • The 3-year average PS ratio of 8.1x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 19% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.95%
Healthcare1.15%
Healthtech2.11%
Life Sciences1.60%
Pharma1.46%
Biotech0.87%
Medical Equipment-0.96%
Healthcare Services-4.68%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.7x.
    • Analysts are expecting annual earnings growth of 18.3%, which is higher than its past year's earnings growth of 9.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 304.951.8%
+DKK 24.3b		-14.5%PE11.6x
COLO B ColoplastDKK 454.202.3%
+DKK 2.3b		-25.6%PE37x
BAVA Bavarian NordicDKK 212.6010.0%
+DKK 1.3b		-10.3%PE10.4x
GMAB GenmabDKK 2.16k0.3%
+DKK 417.9m		36.0%PE25.5x
CHEMM ChemoMetecDKK 492.001.9%
+DKK 156.6m		-4.6%PE48.4x

Latest News

AMBU B
DKK 66.05
Ambu
7D
-13.2%
1Y
-32.5%
BAVA
DKK 212.60
Bavarian Nordic
7D
10.0%
1Y
-10.3%
GUBRA
DKK 400.00
Gubra
7D
1.3%
1Y
2.6%
Analysis Article • Aug 26

Analyst Forecasts For Gubra A/S (CPH:GUBRA) Are Surging Higher

Celebrations may be in order for Gubra A/S ( CPH:GUBRA ) shareholders, with the analysts delivering a significant...
COLO B
DKK 454.20
Coloplast
7D
2.3%
1Y
-25.6%
New Narrative • Aug 25

Coloplast: A Rare Entry Point in Quality Healthcare

Republishing Note This article was originally published on my Substack on the 2nd of July 2026 and is republished here for wider distribution. Note: This report has been corrected since publication.
NOVO B
DKK 304.95
Novo Nordisk
7D
1.8%
1Y
-14.5%
DEMANT
DKK 284.80
Demant
7D
-2.1%
1Y
16.4%
HLUN B
DKK 41.80
H. Lundbeck
7D
-1.6%
1Y
3.1%
Narrative Update • Aug 23

HLUN B: Advancing Neuroscience Pipeline Will Support Future Upside Potential

Analysts have raised their fair value estimate for H. Lundbeck from DKK 47.21 to DKK 48.73.
ALK B
DKK 210.20
ALK-Abelló
7D
-6.0%
1Y
5.4%
GMAB
DKK 2,159.00
Genmab
7D
0.3%
1Y
36.0%
Narrative Update • Aug 21

GMAB: Upcoming Oncology Readouts Will Support Commercial Transition And Offset Patent Cliff

Genmab's updated analyst price target has shifted modestly to DKK 2,930, as analysts factor in higher assumed revenue growth, a slightly lower profit margin profile, a higher discount rate and a lower future P/E multiple, supported by recent research citing confidence in Epkinly, rinatabart sesutecan and petosemtamab, stronger Q2 results, raised 2026 guidance and inclusion on a conviction list. Analyst Commentary Recent Street research on Genmab points to a cluster of supportive views, with several bullish analysts lifting price targets and upgrading ratings following Q2 results, updated 2026 guidance and progress across key oncology assets.
STENO
DKK 0.94
Stenocare
7D
-7.5%
1Y
-30.6%
ZEAL
DKK 314.90
Zealand Pharma
7D
-2.0%
1Y
-25.7%
Analysis Article • Aug 18

Earnings Beat: Zealand Pharma A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of second-quarter numbers that could potentially...
PEG
DKK 0.088
Pharma Equity Group
7D
5.0%
1Y
-38.0%
CHEMM
DKK 492.00
ChemoMetec
7D
1.9%
1Y
-4.6%
EMBLA
DKK 29.15
Embla Medical hf
7D
-2.0%
1Y
-9.2%
Analysis Article • Jul 24

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
SMSMED
DKK 2.85
Scandinavian Medical Solutions
7D
-4.7%
1Y
-32.1%
NNIT
DKK 40.00
NNIT
7D
1.7%
1Y
-33.8%